|

Received: 9 June 2021    Accepted: 13 July 2021

DOI: 10.1111/jocd.14352

REVIEW ARTICLE

Cannabinoids for skin diseases and hair regrowth

Aditya K. Gupta MD, PhD1,2 | Mesbah Talukder PhD2

1
Division of Dermatology, Department of
Medicine, University of Toronto, Toronto,
Ontario, Canada
2
Mediprobe Research Inc, London,
Ontario, Canada
Correspondence
Aditya K. Gupta, 645 Windermere Road,
London, Ontario, N5X 2P1, Canada.
Email: agupta@mediproberesearch.com
Abstract
The use of cannabis for skin diseases and hair regrowth is at the preliminary stage.
Legalization: Many countries have approved cannabis for medical use; however, four
countries Canada, Uruguay, South Africa, and Georgia have legalized it for both medi-
cal and recreational purposes.
The endocannabinoid system: The endocannabinoid system may maintain skin ho-
meostasis; two notable endocannabinoids include 2-­Arachidonoylglycerol (2-­AG) and
N-­arachidonoylethanolamine (AEA).
Routes of administration and pharmacokinetics: Topical cannabinoids can avoid the
first-­pass metabolism and reduce respiratory side effects; however, the high hydro-
phobicity of cannabinoids may hinder percutaneous absorption.
Skin disorders and hair growth: Human clinical studies suggest that cannabinoids
may be used in eczema, acne, pruritus, and systemic sclerosis treatment. Cannabidiol
(CBD) may enhance hair growth via multiple mechanisms.
Safety: Topical cannabis may cause mild side effects such as pruritus, burning, er-
ythema, and stinging; they are relatively safer than inhalation and oral cannabis.
Cannabis use may be associated with allergic symptoms and reduced immune re-
sponse to live vaccination.
Cannabinoids in practice: Despite growing interest, dermatologists should be cau-
tious prescribing cannabinoids due to insufficient clinical data on both efficacy and
safety.

KEYWORDS
cannabidiol, cannabinoids, endocannabinoid system, hair growth, skin diseases

1  |  I NTRO D U C TI O N anxiety, cancer-­related pain, and anorexia, chemotherapy-­induced

Cannabis use for dermatologic conditions is still at an early stage;
1
however, interest exhibited by patients is growing. Cannabidiol
(CBD), a relatively less psychoactive phytocannabinoid, has been
marketed as an analgesic, anti-­
inflammatory, anti-­
wrinkle, and
moisturizer. 2 There are claims that it may be a remedy for pruritus,
2
psoriasis, acne, eczema, and skin aging. Cannabis is also used for
neuropathic pain, pediatric seizures, and multiple sclerosis treat-
3
ment. Several studies have suggested that it may be indicated in
nausea, and vomiting, but the evidence is inconclusive. 3
Depending on the source, cannabinoids can be classified into
three groups: (a) endocannabinoids (naturally produced in human
or animal bodies); (b) phytocannabinoids (sourced from cannabis
plants, Cannabis sativa/indica); and (c) synthetic cannabinoids (syn-
thesized in the laboratory). Cannabis, also known as “marijuana,”
contains more than 140 phytocannabinoids, including tetrahydro-
cannabinol (THC) and CBD.3-­5 Table 16 provides representative ex-
amples of cannabinoids from each group.6 This article reviews the

J Cosmet Dermatol. 2021;20:2703–2711. wileyonlinelibrary.com/journal/jocd © 2021 Wiley Periodicals LLC     2703 |

 |
2704      GUPTA and TALUKDER

TA B L E 1  Representative examples of
Endocannabinoids Phytocannabinoids Synthetic cannabinoids
cannabinoids6
2-­Arachidonoylglycerol Delta9-­tetrahydrocannabinol JWH−133
(2-­AG) (THC)
N-­arachidonoylethanolamine Cannabidiol (CBD) WIN−55,212–­2
(AEA)
Palmitoyl ethanolamide Cannabinol (CBN) (R)-­methanandamide (MET)
(PEA)a 
N-­arachidonoyl dopamine Cannabigerol (CBG) CP 55,940
Virodhamine Cannabidiolicacid (CBDA)
a
PEA is not a true endocannabinoid. It does not directly bind the cannabinoid receptors—­only
promotes the binding of other endocannabinoids.

F I G U R E 1  Search strategy and the

articles’ exclusion criteria

legalization status, pharmacokinetics, routes of administration, and
current practice norms of cannabinoids, with a focus on skin dis-
eases and hair regrowth.
2  |  S E A RC H S TR ATEG Y A N D M E TH O D
We performed a structured and comprehensive search on PubMed
and Google scholar. The principal search strategy focused on using
the advanced search builder feature of PubMed—­various keywords
and MeSH terms were used for the skin endocannabinoid system
(ECS), pharmacokinetics, routes of administration, cannabinoids’
use in skin disorders treatment, clinical trials, cannabinoids and hair
growth, risk of using cannabinoids, and its use in practice. A comple-
mentary search using similar keywords was conducted on Google
scholar. We also conducted further web-­based searches on Google,
RxTx database, and RxFiles to find relevant “grey literature” (e.g.,
standard practice norms, non-­journal publications, reports, web-
sites, etc.). Additionally, we hand-­searched the bibliographies of se-
lected articles to identify grey literature sources. Figure 1 details the
search strategy and the exclusion criteria.
quality herb.7 In ancient India, cannabis was
as a harmless high-­
widely used in religious festivals and also for medicinal purposes as
an anesthetic, analgesic, anti-­parasitic, and so forth.7 The Buddhist
monks of Tibet considered cannabis as a sacred plant and frequently
used it for meditation in “Tantric Buddhism.”7 Perhaps the first re-
corded warning about cannabis came from Galen, a Greek physi-
cian in the Roman regime. He recommended not to consume excess
hemp seed cakes during dinner parties, which was a common prac-
tice at that time7; hemp is a Cannabis sativa plant variety.7 In 1984,
Pope Innocent VIII declared cannabis sinful and prohibited its use.7
The attitude toward cannabis may be changing. Cannabis is ap-
proved for medical use in many countries; however, only Canada,
Uruguay, South Africa, and Georgia have legalized it for both medi-
cal and recreational purposes. In the USA, different states have ad-
opted different cannabis policies.8 Table 29-­11 compares the timeline
of cannabis legalization in the USA and Canada.9-­11 Europe is rela-
tively behind, with the legalization of cannabis for medical use in the
Netherlands, Germany, and Italy.8
4  |  TH E S K I N E N D O C A N N A B I N O I D
S YS TE M

3  |  H I S TO RY A N D C A N N A B I S The ECS in skin consists of three main components, (a) endo-

LEG A LIZ ATI O N cannabinoids such as 2-­Arachidonoylglycerol (2-­AG) and N-­
arachidonoylethanolamine (AEA), (b) endocannabinoid receptors,
Cannabis has been used since prehistoric times. Shen Nung, the fa- and (c) the enzymes responsible for endocannabinoids synthesis
ther of Chinese medicine, lived around 2700 BCE, regarded cannabis and breakdown.12 The ECS perhaps maintains skin homeostasis;
GUPTA and TALUKDER |
      2705

TA B L E 2  Timeline of Cannabis legalization in the USA and Canada9-­11

USA Canada

1937 The Marihuana Tax Act imposed a high tax on cannabis 1923 Narcotics Drug Act Amendment Bill made
cannabis illegal
1793 Oregon, the first state that lessened the penalty for possessing 2001 Health Canada launched medical
cannabis marijuana program
1996 California legalized the medical use of cannabis 2015 A task force was formed for the
legalization of cannabis possession
2012 Colorado and Washington legalized the recreational use of cannabis 2018 The Cannabis Act legalized the
recreational use of cannabis
April 2021 17 states, 2 territories, and the District of Columbia legalized
recreational use of cannabis
May 2021 36 states and 4 territories legalized the medical use of cannabis

F I G U R E 2  The endocannabinoid
system (ECS) in skin.12,13 2-­AG,
2-­Arachidonoylglycerol; AEA, N-­
arachidonoylethanolamine; CB1,
Cannabinoid receptor type 1; CB2,
Cannabinoid receptor type 2; GPR55,
G protein-­coupled receptor 55; PPAR-­γ,
Peroxisome proliferator-­activated
receptor-­γ; TRPV, Transient receptor
potential cation channels (vanilloid)

its dysregulation may lead to skin disorders such as acne, pruri-

tus, atopic dermatitis, skin pigmentation, hair loss, or growth.12,13
Endocannabinoids are synthesized in hair follicles, epidermis, and
sebaceous glands and released in particular amounts depend-
ing on the need to maintain normal physiological function.13 They
bind to various receptors, but two classic receptors—­cannabinoid
receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) ex-
pressed in nearly all types of skin cells, play vital roles in their action
(Figure 2).12,13 Figure 2 illustrates the function of endocannabinoids
on various types of skin cells.12,13

5  |   RO U TE S O F A D M I N I S TR ATI O N A N D
PH A R M ACO K I N E TI C S

The clinical trials to treat skin diseases have predominantly investi-

gated topical cannabinoids14-­19; however, some have explored oral
cannabinoids (Figure 3). 20,21 Other less common routes are inhala-
tion, sublingual, or oromucosal (e.g., lozenges, sprays), rectal (e.g.,
suppositories), intravenous (e.g., injection), and so forth. 22 The F I G U R E 3  Cannabinoids’ common routes of administration
 |
2706      GUPTA and TALUKDER

TA B L E 3  Pharmacokinetics of cannabinoids3,23,24

Topical Oral Inhalation

Absorption Percutaneous absorption of CBD is 10 Bioavailability: 6%–­20% Bioavailability: 15%–­50%

times higher than THC
An 8 mg THC transdermal patch Onset of action: 30–­60 min, up to 1–­3 h Onset of action: 5–­10 min
maintained steady-­state plasma Peak action: 2–­4 h, up to 6 h Peak action: 10–­20 min
concentration of 4.4 ng/ml for 48 h
(guinea pig model). The concentration Duration of action: 4–­6 h, up to 24 h Duration of action: 2–­4 h, up to 24 h
reached the steady state within 1.4 h of (adult); 6–­12 h, up to 36 h. (children)
its application
Distribution THC and CBD are highly hydrophobic; therefore, readily distributed into adipose tissues
Distributed throughout heart, lung, brain, and liver
Vd: ~10 L/Kg (THC); ~32 L/Kg (CBD)
Protein binding: approximately 97% (THC)
Metabolism THC and CBD extensively metabolized in the liver by cytochrome P450 isoenzymes
Excretion THC and CBD excreted in the feces and in the urine.
Half-­life: 1–­3  days

Abbreviations: CBD, cannabidiol; THC, tetrahydrocannabinol; Vd, volume of distribution.

pharmacokinetic properties of cannabinoids, especially absorption,
3,23,24
vary depending on the route of administration (Table 3).
5.1  |  Topical
The topical application of cannabinoids for skin diseases may be ad-
vantageous because of the ability to act locally at the disease site.
Topical cannabinoids also have two added advantages compared
to inhalation and oral routes. First, it is expected to cause fewer
respiratory side effects than inhalation dosing. Second, unlike oral
cannabinoids, it can avoid the first-­pass metabolism. 25 Arguably, the
substance abuse potential is lower with cannabinoid transdermal
25
patches because it releases the drug slowly from the reservoir.
However, the hydrophobic nature of cannabinoids may hinder per-
23
cutaneous absorption, leading to reduced therapeutic effect.
respiratory symptoms such as pulmonary function reduction, bron-
chitis, coughing, and wheezing. 22 “Canna-­
vaping,” on the other
hand, is an emerging alternative to smoking 22—­where an electronic
device heats cannabis to produce vapor of water and cannabinoids
for inhalation. 22 The vapor contains less carbon monoxide and toxic
substances than the smoke, suggesting it might cause relatively less
respiratory distress and other relevant side effects. 22
6  |  H U M A N C LI N I C A L S T U D I E S
This section discusses eight human clinical studies that investigated
cannabinoids’ use in various skin disorders treatment. The articles
were selected based on the inclusion and exclusion criteria described
in the search strategy and method section. Table 414-­21 briefly sum-
marizes the studies.

5.2  |  Oral 6.1  |  Eczema

Oral cannabinoids, especially “edible cannabinoids” (cannabis-­
infused foods and beverages), are gradually becoming popular among
users. 22 However, its potency and bioavailability are unpredictable—­
the onset is often delayed, which may provoke the user to consume
more, eventually leading to overdose and intoxication. 22
5.3  |  Inhalation
Cannabis can be inhaled either by smoking or by “canna-­vaping.”22
22
Smoking is probably the most popular route in North American —­a
recent US survey found that more than 90% of adult users pre-
ferred smoking. 22 However, cannabis smoking is associated with
A randomized, single-­blinded crossover study was conducted on a
small sample size of 20 atopic dermatitis patients, who were catego-
rized into two groups—­the experimental group took 30 ml hempseed
oil daily by mouth, and the control group took olive oil at the same
dose, route, and frequency. 20 Hempseed oil significantly improved
serum fatty acid profiles and atopic dermatitis symptoms such as
skin dryness and itchiness. 20 The improvement could be attributed
to omega-­
6 and omega-­
3 polyunsaturated fatty acids found in
hempseed oil. 20 No severe side effect was observed; however, only
one patient discontinued due to the poor taste of hempseed oil. 20
Palmitoylethanolamide (PEA), an endogenous fatty acid and
regulator of the ECS in the skin, may bind to the CB2 receptor
on mast cells, stabilize them, and result in downregulation of T
 GUPTA and TALUKDER

TA B L E 4  A summary of cannabinoid clinical studies conducted on human subjects14-­21

Disease Study Intervention/ cannabinoids Outcome Side effects

Eczema Callway et al. Hempseed oil Improved skin dryness and itchiness No side effect, but one patient discontinued due
Improved serum fatty acid profiles to hempseed oil's poor taste

Del Rosso PEA-­containing nonsteroidal cream plus topical Rapid remedy of initial disease flare Mild, transient stinging
mid-­potency corticosteroids Delayed the next disease flare by
approximately 28 days
Eberlein et al. PEA-­containing cream Improved disease symptoms Minor side effects such as pruritus, burning,
Improved sleep quality erythema, etc. in 1% of the total study
population
Reduced use of topical corticosteroids
Yuan et al. PEA-­/AEA-­(0.3%/0.21%) containing cream Improved disease symptoms No side effect observed
Improved skin hydration
Acne Ali et al. 3% cannabis seed extract cream Significantly reduced sebum and erythema No side effect reported
content
Pruritus Szepietowski et al. PEA-­and AEA-­containing cream Completely reduced pruritus in 38% of the No side effect reported
patients
Completely reduced xerosis in 81% of the
patients
Visse et al. PEA-­containing lotion No significant difference between vehicle Minor side effects such as pruritus, stinging,
and the lotion scaling, or reddening
Systemic sclerosis Spiera et al. Oral Lenabasum CRISS score significantly improved No severe drug-­related side effect
Minor side effects such as dizziness, fatigue,
headache, arthralgia, upper respiratory tract
infection, nausea, and decreased forced vital
capacity

Abbreviations: AEA, N-­acetylethanolamine; CRISS score, combined response index in diffuse cutaneous systemic sclerosis score; PEA, N-­palmitoylethanolamine.
|
      2707
 |
2708      GUPTA and TALUKDER
helper cell type 2-­m ediated response in atopic dermatitis.16 An
investigator-­b linded, randomized, split-­b ody clinical study, con-
ducted on 43 patients (18 adults and 25 children), compared (i)
PEA-­containing cream plus topical mid-­p otency corticosteroids
versus (ii) moisturizer cream plus the same corticosteroids for
16
six weeks. Each patient applied two creams on two sides of the
body.16 The use of PEA rapidly cleared the initial disease flare and
also delayed the next flare by approximately 28 days; however, the
statistical significance of the outcomes was not mentioned in the
article.16 Two of 25 children experienced a mild, transient stinging
using PEA-­containing cream.16
Eberlein and his group conducted a prospective and obser-
vational study on 2456 atopic eczema patients where they ap-
plied PEA-­containing cream at least twice a day for four to six
weeks.17 The PEA cream reduced disease parameters such as dry-
ness, scaling, erythema, pruritus, excoriation, and lichenification
17
in 58.6% of the patients.  Patients also reported significant re-
duction in pruritus and improvement of sleep quality.17 Moreover,
study subjects were able to reduce topical steroid application.17
Side effects (1% subjects) were minor and included pruritus,
burning, and erythema.17 The study lacked a control group and
randomization.
A double-­blinded, randomized trial (N  = 60 patients) showed
that PEA-­/AEA (0.3%/0.21%)-­containing cream applied twice
daily for 28 days significantly (p  < 0.05) improved asteatotic ec-
zema symptoms (skin scaling and itching) compared to the control
cream.19 More importantly, the skin hydration was considerably bet-
19
ter in the PEA-­/AEA-­cream group.
6.2  |  Acne
14
Excessive sebum production is associated with acne development.
In a single-­
blinded, randomized trial, 3% cannabis seed extract
cream significantly reduced the sebum production compared to the
base cream (control).14 Each of 11 patients who participated in the
trial applied the cannabis cream on one side of the face and the base
cream on the other side for three months.14 The authors did not re-
port any side effects.
6.3  |  Pruritus
Approximately 38% of 21 uremic pruritus patients reported a de-
crease in pruritus when applying PEA-­ and AEA-­containing cream
twice daily for three weeks in an observational, non-­blinded, pro-
spective cohort study.15 Also, the xerosis was reduced in 81% of the
15
patients. However, a randomized, single-­blinded study conducted
on 100 chronic pruritus patients did not find any significant differ-
ence between PEA-­containing lotion and the vehicle in reducing
pruritus.18 Six patients from both experimental and control groups
reported minor side effects such as pruritus, stinging, scaling, or
reddening.18
6.4  |  Systemic sclerosis
Lenabasum, a synthetic CB2 receptor agonist, when used in sys-
temic sclerosis significantly improved the CRISS score (Combined
Response Index in diffuse cutaneous Systemic Sclerosis) com-
pared to the placebo in a phase II, randomized, double-­b linded
study (Lenabasum CRISS score: 0.33 vs. placebo CRISS score:
0.00). 21 Twenty-­s even of 42 patients took oral Lenabasum, and 15
patients took placebo. 21 The doses of Lenabasum were 5 mg once
a day, 20 mg once a day, or 20 mg twice a day for the first four
weeks, then 20 mg once a day for eight weeks. 21 Approximately
63% of the Lenabasum group versus 60% of the placebo group
reported side effects such as dizziness, fatigue, headache, ar-
thralgia, upper respiratory tract infection, nausea, and decreased
forced vital capacity, but no severe drug-­related side effects were
observed. 21
7  |  C B D A N D H A I R R EG ROW TH
Being a negative allosteric modulator to the CB1 receptor, CBD may
promote hair growth because the stimulated CB1 receptor hinders
the hair shaft elongation, reduces keratinocyte proliferation, and in-
duces premature hair follicle regression (Figure 4). 26,27 It may also
help in maintaining the anagen phase by differentiating dermal pro-
genitor cells into new hair follicles through the Wnt/β-­catenin path-
way. 27,28 Figure 426-­29 illustrates the proposed mechanisms of CBD
in hair regrowth.
CBD is also a TRPV1 (Vanilloid receptor-­1) and TRPV4 (Vanilloid
receptor-­4) agonist. 27 The activation of TRPV1 negatively impacts
hair growth, but excessive activation desensitizes the recep-
tor and may indirectly help growing hairs (Figure 4). 27 An ex vivo
study found that the high concentration of CBD (10 µM) activated
TRPV4 receptors and significantly reduced hair shaft development
and induced apoptosis. However, at a low concentration (0.1 µM),
it increased hair shaft elongation perhaps via adenosine receptor
(Figure 4). 29
A recent study conducted on 35 AGA patients (28 males, 7 fe-
males) showed that once-­daily application of CBD-­rich hemp oil
for six months (3–­4 gm/day) increased the non-­vellus hair count by
93.5%. Males experienced slightly better outcomes than females;
neither group reported any significant side effects. 27
8  |  S A FE T Y
Figure 53 illustrates the common side effects of cannabis use.
8.1  |  Topical cannabis
The human clinical studies report only minor side effects such as
pruritus, burning, erythema, and stinging.16-­18 Topical cannabis
GUPTA and TALUKDER |
      2709

F I G U R E 4  Proposed mechanisms of CBD in hair regrowth. 26-­29 β-­cat: Beta-­catenin; CBD: Cannabidiol; CB1: Cannabinoid receptor type 1;
TRPV1: Transient receptor potential cation channel subfamily V member 1; TRPV4: Transient receptor potential cation channel subfamily V
member 4

F I G U R E 5  Common side effects of

Cannabis use.3 “High state”: Euphoria,
relaxation, distorted perception

may not be associated with severe harm.30 However, buying topi-
cal cannabis products from non-­regulated or illegal sources may be
concerning due to the unknown pesticide exposure, impurities, or
30
unspecified potency. It may significantly increase the risk of infec-
30
tion if applied to the compromised skin.  Patients should be extra
careful using THC-­containing topical products on skin wounds or
cracks since it might increase the systemic absorption and cause side
30
effects such as euphoria.
8.2  |  Cannabis allergy
Cannabis allergy incidences are thought to be under-­reported.5 The
allergy response may be administration route-­dependent. For exam-
ple, a patient who ingested hempseed developed an anaphylactic
reaction, but the same patient did not show any allergic symptoms
with cannabis smoking.5 Several other studies also reported aller-
gic responses to cannabis, hempseed, or both. Cannabis also shows
 |
2710      GUPTA and TALUKDER
TA B L E 5  Misconceptions and facts about cannabis32,33
Misconceptions Fact
Cannabis is better than other With cannabis, toxic
available therapies. overdose is highly
unlikely.
Some cannabinoids, such as CBD,
do not have side effects.
Usually, cannabis does not cause
addiction.
cross-­reactivity—­a study conducted on regular drug users found that
half of them, who were allergic to tobacco or tomato, were also sen-
sitive to cannabis.5
8.3  |  Cannabis and immunity
Cannabis may reduce the immune response to live immunizations
such as the smallpox vaccine.31 A study on mice showed that THC
and cannabis resin reduced antibody production and prolonged the
viral infection symptoms.31 Moreover, smoking or oral cannabis may
31
make the users more prone to cutaneous viral infections.
9  |  C A N N A B I N O I DS I N PR AC TI C E
9.1  |  Treatment approach
Until now, cannabis use in hair regrowth and skin diseases is un-
32
derstudied.  We do not have clinical data that show cannabinoid-­
based formulations better than existing evidence-­
based
medications.32Therefore, it is recommended for dermatologists to
try all standard therapies prior to prescribing cannabinoids.32,33 If
the decision is taken to start cannabinoid therapy as a trial, it should
be started at a low dose—­“start low, go slow” approach and is rec-
ommended to stop if the therapy does not work or causes adverse
effects.32,33 Cannabinoid therapies are not recommended for breast-
feeding and pregnant women, young patients under 25 years, and
patients with drug abuse, and psychosis history.33 Table 532,33 sum-
marizes common misconceptions and facts about cannabis.
9.2  |  CBD and psychoactive side effects
Since CBD is less psychoactive than THC, it is widely used in various
dermatologic formulations.32 However, dermatologists may note that
CBD can still cause dizziness, drowsiness, and mood fluctuations.32
9.3  |  Cannabis overdose and addiction risk
Although toxic overdose with cannabis is highly unlikely, it does
not indicate that it is entirely safe.32 Excessive use of cannabis or
cannabinoid formulations may endanger the patients’ safety.32
Perhaps topical cannabis possesses less addiction risk, but inhala-
tion or oral cannabinoid users may experience cravings and find it
hard to discontinue.32,33 In such cases, dermatologists may consider
gradual dose tapering.32,33
10  |  CO N C LU S I O N
The preliminary human clinical studies indicate that cannabinoids
may improve eczema, acne, skin pruritus, systemic sclerosis, and hair
growth. Dermatologists are now more open to prescribing cannabis
formulation. According to a recent survey, 86% of 531 dermatologists
were positive about topical cannabinoids, and 71% said yes to oral
forms.34 However, more high-­quality, randomized, double-­blinded,
and placebo-­controlled human clinical trials are still required to es-
tablish the efficacy and safety of cannabinoid formulations.
C O N FL I C T O F I N T E R E S T
The author declares that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.
E T H I C A L S TAT E M E N T
Authors declare human ethics approval was not needed for this
study.
AU T H O R C O N T R I B U T I O N S
Aditya K. Gupta was responsible for the conceptualization, design,
and editing of the manuscript. Mesbah Talukder drafted the manu-
script. Aditya K. Gupta and Mesbah Talukder revised it. Both authors
have approved the submitted version.
REFERENCES
1. Cather J. CBD in the holistic practice of dermatology. 2020;
Accessed 01 June, 2021. https://pract​icald​ermat​ology.com/artic​
les/2020-­july/cbd-­in-­the-­holis​tic-­pract​ice-­of-­derma​tology
2. Jhawar N, Schoenberg E, Wang JV, Saedi N. The growing trend of
cannabidiol in skincare products. Clin Dermatol. 2019;37(3):279-­281.
3. RxTx. Cannabis (CPhA Monograph). 2018; Accessed 18 May, 2021.
https://www- ­e -­t hera ​ p euti ​ c s- ­c a.myacc​ e ss.libra ​ r y.utoro ​ n to.ca/
search
4. Crawley A, LeBras M, Regier L Cannabinoids: overview (RxFiles).
2021; Accessed 18 May, 2021 www.RxFil​es.ca
5. Dhadwal G, Kirchhof MG. The risks and benefits of cannabis in the
dermatology clinic. J Cutan Med Surg. 2018;22(2):194-­199.
6. Eagleston LR, Kalani NK, Patel RR, Flaten HK, Dunnick CA,
Dellavalle RP. Cannabinoids in dermatology: a scoping review.
Dermatol Online J. 2018;24(6)40706.
7. Study documents humanity’s use of marijuana over 10,000 years
of history. 2021; Accessed 19 May, 2021. https://www.marij​
uanam​oment.net/study​-­docum​ents-­human​itys-­use-­of-­marij​uana-­
over-­10000 ​-­years​-­of-­histo​r y/
8. Papaseit E, Pérez-­Mañá C, Pérez-­Acevedo AP, et al. Cannabinoids:
from pot to lab. Int J Med Sci. 2018;15(12):1286.
9. National conference of state legislatures. 2021; Accessed 19 May,
2021. https://www.ncsl.org/resea​rch/healt​h/state​-­medic​al-­marij​
uana-­laws.aspx
GUPTA and TALUKDER
10. Milestones in U.S. marijuana laws. Accessed 19 May, 2021. https://
archi​ve.nytim​es.com/www.nytim​es.com/inter​activ​e/2013/10/27/
us/marij​uana-­legal​izati​on-­timel​ine.html#/#time2​83_8117
11. Cannabis in Canada. Accessed 19 May, 2021. https://www.canada.
ca/en/servi​ces/healt​h/campa​igns/canna​bis/canad​ians.html
24. Cannabidiol (CBD) critical review report; Expert Committee on
12. Baswan SM, Klosner AE, Glynn K, et al. Therapeutic potential of
cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig
Dermatol. 2020;13:927.
13. Inroduction to the skin endocannabinoid system -­Phytecs.
Accessed 31 May, 2021. http://www.phyte​c s.com/tour-­the-­ecs/
the-­ecs-­in-­skin/
14. Ali A, Akhtar N. The safety and efficacy of 3% cannabis seeds
extract cream for reduction of human cheek skin sebum and ery-
thema content. Pak J Pharm Sci. 2015;28(4):1389-­1395.
15. Szepietowski J C, Szepietowski T, Reich A. Efficacy and tolerance of
the cream containing structured physiological lipids with endocan-
nabinoids in the treatment of uremic pruritus: a preliminary study.
Acta Dermatovenerol Croat. 2005;13(2):97-­103.
16. Del Rosso JQ. Use of a palmitoylethanolamide-­containing nonste-
roidal cream for treating atopic dermatitis: impact on the duration of
response and time between flares. Cosmet Dermatol. 2007;20(4):4.
17. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treat-
ment of atopic eczema: assessment of an emollient containing
N-­palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol
Venereol. 2008;22(1):73-­82.
18. Visse K, Blome C, Phan NQ, Augustin M, Ständer S. Efficacy of
body lotion containing N-­palmitoylethanolamine in subjects with
chronic pruritus due to dry skin: a dermatocosmetic study. Acta
Derm Venereol. 2017;97(5):639-­6 41.
19. Yuan C, Wang X-­M, Guichard A, et al. N-­palmitoylethanolamine and
N-­acetylethanolamine are effective in asteatotic eczema: results of
a randomized, double-­blind, controlled study in 60 patients. Clin
Interv Aging. 2014;9:1163.
20. Callaway J, Schwab U, Harvima I, et al. Efficacy of dietary hemp-
seed oil in patients with atopic dermatitis. J Dermatolog Treat.
2005;16(2):87-­94.
21. Spiera R, Hummers L, Chung L, et al. Safety and efficacy of Lenabasum
in a phase II, randomized, placebo-­controlled trial in adults with
systemic sclerosis. Arthritis Rheumatol. 2020;72(8):1350-­1360.
22. Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of ad-
ministration for cannabis use–­basic prevalence and related health
outcomes: A scoping review and synthesis. Int J Drug Policy.
2018;52:87-­96.
23. Information for health care professionals: cannabis (marihuana,
marijuana) and the cannabinoids. 2018; Accessed 21 May, 2021.
|
      2711
https://www.canada.ca/conte​nt/dam/hc-­sc/docum​ents/servi​ces/
drugs​-­m edic ​a tion/​c anna​b is/infor​m atio​n -­m edic ​a l-­p ract​i tion​e rs/
infor ​m atio​n -­h ealt ​h -­c are-­p rofe ​s sion​a ls-­c anna ​b is-­c anna ​b inoi​d s-­
eng.pdf
Drug Dependance, 40th meeting, Geneva. Accessed 31 May, 2021.
https://www.who.int/medic​i nes/acces​s/contr​o lled​-­s ubst ​a nces/​
Canna​bidio​lCrit​icalR​eview.pdf
25. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers.
2007;4(8):1770.
26. Telek A, Bíró T, Bodó E, et al. Inhibition of human hair follicle growth
by endo-­and exocannabinoids. FASEB J. 2007;21(13):3534-­3541.
27. Smith G, Satino J. Hair Regrowth with cannabidiol (CBD)-­rich hemp
extract. Cannabis. 2021;4(1):53-­59.
28. Vallée A, Lecarpentier Y, Guillevin R, Vallée J-­N. Effects of canna-
bidiol interactions with Wnt/β-­c atenin pathway and PPARγ on ox-
idative stress and neuroinflammation in alzheimer's disease. Acta
Biochim Biophys Sin. 2017;49(10):853-­866.
29. Szabó IL, Lisztes E, Béke G, et al. The phytocannabinoid
(-­)-­c annabidiol (CBD) operates as a complex, differential modula-
tor of human hair growth: anti-­inflammatory submicromolar ver-
sus hair growth inhibitory micromolar effects. J Invest Dermatol.
2020;140(2):484-­488.
3 0. Bunka D, LeBras M, Oroz I. Topical Cannabis: Does it Live Up to
its Presumed Potential? (RxFiles). 2019; Accessed 18 May, 2021.
www.RxFil​es.ca
31. Antley CM, Anderson R, Margulies J. Cannabis in dermatology. In:
Cannabis in Medicine. Springer; 2020:383-­4 00.
32. A booklet for people thinking about starting medical cannabis
(RxFiles). Accessed 18 May, 2021. www.RxFil​es.ca
33. Cannabinoids/medical cannabis Q&A (RxFiles). 2019; Accessed 18
May, 2021. www.RxFil​es.ca
3 4. Robinson E, Murphy E, Friedman A. Knowledge, attitudes, and per-
ceptions of cannabinoids in the dermatology community. J Drugs
Dermatol. 2018;17(12):1273-­1278.
How to cite this article: Gupta AK, Talukder M. Cannabinoids
for skin diseases and hair regrowth. J Cosmet Dermatol.
2021;20:2703–­2711. https://doi.org/10.1111/jocd.14352